Recce Pharmaceuticals signs second US Army CRADA

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has confirmed a second Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR). This collaboration will focus on evaluating RECCE® 327 Gel as a potential treatment for infected burn wounds.

Addressing a Critical Need

According to James Graham, Managing Director and CEO of Recce Pharmaceuticals, infected burn wounds represent a significant medical challenge, particularly for warfighters on the front lines. This second CRADA with the US Army, and the company’s third research program with the US Department of defence, underscores the importance of finding effective treatments for these complex injuries.

Did You Know? Recce Pharmaceuticals is, according to the World Health Organization, the only clinical-stage synthetic antibiotic currently in development.

A Novel Approach to Antibiotic Resistance

The core of Recce Pharmaceuticals’ approach lies in its synthetic antibiotic, RECCE® 327 Gel. Traditional antibiotics, derived from natural sources, often face the problem of bacterial resistance as organisms evolve to survive exposure. RECCE® 327 Gel is designed to overcome this resistance, continuing to work effectively even with repeated use.

Expanding Applications

While the current CRADA focuses on burn wound infections, the potential applications of RECCE® 327 Gel extend beyond the battlefield. The same formulation is currently undergoing Phase III clinical trials for the treatment of diabetic foot infections. This suggests a broader range of potential uses in both military and civilian healthcare settings, including possible applications for Veterans Affairs healthcare.

Expert Insight: The US Army’s continued collaboration with Recce Pharmaceuticals highlights the critical need for innovative solutions to combat antibiotic resistance, a growing threat to both military personnel and the general population. The focus on burn wounds, a particularly vulnerable area for infection, demonstrates a targeted approach to addressing a specific and serious medical challenge.

Financial Perspective

Edison Research has recently valued Recce Pharmaceuticals at $3 per share. James Graham suggests that, given the significance of antibiotic resistance as a global health threat and the unique position of RECCE® 327 Gel as a new class of antibiotic, this valuation may be conservative.

Frequently Asked Questions

What is a CRADA?

A CRADA, or Cooperative Research and Development Agreement, is a partnership between a government agency – in this case, the US Army Institute of Surgical Research – and a private company, like Recce Pharmaceuticals, to collaborate on research and development.

What makes RECCE® 327 Gel different from other antibiotics?

RECCE® 327 Gel is a synthetic antibiotic, meaning it is not derived from natural sources. This synthetic design is intended to overcome the problem of bacterial resistance that often develops with traditional antibiotics.

What other research is Recce Pharmaceuticals involved in?

Besides the two CRADAs with the US Army, Recce Pharmaceuticals has a third research program with the US Department of defence. RECCE® 327 Gel is in Phase III clinical trials for the treatment of diabetic foot infections.

As research progresses and clinical trials continue, what role do you envision for synthetic antibiotics in addressing the growing challenge of antibiotic resistance?